PMS-OLMESARTAN TABLET

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

OLMESARTAN MEDOXOMIL

থেকে পাওয়া:

PHARMASCIENCE INC

এটিসি কোড:

C09CA08

INN (আন্তর্জাতিক নাম):

OLMESARTAN MEDOXOMIL

ডোজ:

20MG

ফার্মাসিউটিকাল ফর্ম:

TABLET

রচনা:

OLMESARTAN MEDOXOMIL 20MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

30/100/1000

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0152496002; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2017-05-01

পণ্য বৈশিষ্ট্য

_PMS-OLMESARTAN_
Page
1
of
29
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
PMS-OLMESARTAN
Olmesartan Medoxomil Tablets, USP
Tablets, 20 mg and 40 mg Oral
Angiotensin II AT
1
Receptor Blocker
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
SUBMISSION CONTROL NO: 266034
DATE OF INITIAL AUTHORIZATION:
May 1, 2017
DATE OF REVISION
August 12, 2022
_PMS-OLMESARTAN_
Page
2
of
29
RECENT MAJOR LABEL CHANGES
2 Contraindications, Pregnancy and Breastfeeding
7 Warnings and Precautions, 7.1 Special Populations, Pregnant women
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 4
1.
INDICATIONS
..................................................................................................................
4
Pediatrics
.............................................................................................................................
4
Geriatrics
.............................................................................................................................
4
2.
CONTRAINDICATIONS
................................................................................................
4
3.
SERIOUS WARNINGS AND PRECAUTIONS BOX
................................................... 5
4.
DOSAGE AND ADMINISTRATION
.............................................................................
5
4.1
Dosing Considerations
..................................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.............................................................. 6
4.3
Reconstitution
...............................................................................................................
6
4.4
Administration
...............................................................................................................
6
4.5
Missed Dose
..................................................................................................................